

Received: 2012.09.12
Accepted: 2012.10.18
Published: 2012.10.22

Multicystic peritoneal mesothelioma

Antonios-Apostolos Tentis, Georgios Zorbas, Nicolaos Pallas, Aiki Fiska

Surgical Department, Didimotichon General Hospital, Diagnostiko Center of Pathology, Didimotichon, Greece

Summary

Background: Multicystic peritoneal mesothelioma is a rare disease. It is not certain if it is a benign or a borderline tumor. Although many therapeutic approaches have been used, complete cytoreductive surgery in combination with hyperthermic intraoperative intraperitoneal chemotherapy has gained acceptance.

Case Report: A case of multicystic peritoneal mesothelioma in a 16-year old patient is reported. The patient underwent complete cytoreduction and received intraoperative hyperthermic intraperitoneal chemotherapy. The patient is disease-free one year after surgery.

Conclusions: Complete cytoreductive surgery in combination with hyperthermic intraoperative intraperitoneal chemotherapy appears to be a rational therapeutic approach in multicystic peritoneal mesothelioma.

key words: peritoneal mesothelioma • cytoreductive surgery • hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC)

Full-text PDF: <http://www.amjcaserep.com/fulltxt.php?ICID=883523>

Word count: 462

Tables: –

Figures: 4

References: 14

Author's address: Antonios-Apostolos K. Tentis, Surgical Department, Didimotichon General Hospital, Didimotichon, 68300, Greece, e-mail: atentes@did-hosp.gr

BACKGROUND

Multi-cystic peritoneal mesothelioma is a rare disease and less than 200 cases have been reported in the literature [1,2]. The short-term survival seems to be favorable but after debulking surgery the incidence of recurrence is high [3]. Long-term clinical study has not been reported so far. The disease generally affects women in reproductive age and is not related to asbestos exposure [1,2]. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) has been considered the standard of care for diffuse malignant peritoneal mesothelioma [4–6] and currently has gained acceptance for the treatment of multicystic peritoneal mesothelioma [7]. A rare case of multicystic peritoneal mesothelioma in a 16-year old patient is reported.

CASE REPORT

A 16-year old female patient presented with vague abdominal discomfort and abdominal distention for the last two months. Ultrasound revealed the presence of ascites. Abdominal CT-scan confirmed the presence of ascites with peritoneal implants at the pelvis. Laparoscopy and biopsies showed the presence of multicystic peritoneal mesothelioma. The patient (Figure 1) underwent complete cytoreductive surgery and hyperthermic intraperitoneal intraoperative chemotherapy (Figure 2). Cytoreductive surgery was possible



Figure 1. Greater omentum of the patient with multicystic peritoneal mesothelioma.




Figure 2. The pelvis of the patient with multicystic peritoneal mesothelioma.

by pelvic peritonectomy procedure (resection of the pelvic peritoneum en bloc with the internal female genitalia, and low anterior resection), greater and lesser omentectomy (Figure 3). The patient had an uneventful recovery and one year after initial treatment remains disease free. Final histopathology confirmed the initial diagnosis (Figure 4).

DISCUSSION

Multicystic peritoneal mesothelioma is an intermediate between benign adenomatoid tumor and diffuse malignant peritoneal mesothelioma [2]. The natural history of the disease is still an issue of disagreement [1,2,8]. It is still discussed whether this is a benign or a border-line malignant neoplasm [2]. The recurrence rate in patients that underwent traditional debulking surgery is high [8,9]. A few patients with multicystic peritoneal mesothelioma have been reported to develop diffuse malignant peritoneal mesothelioma after treatment [10,11]. Complete surgical resection has been advocated by most authors as the treatment of choice. More conservative treatments have also been recommended such as laparoscopic debulking, irradiation, systemic or intraperitoneal chemotherapy, laser vaporization, percutaneous cyst drainage, hormone-therapy, sclero-therapy with anthracycline or simple observation with uncertain results [1,2].

The recurrence rate even after complete surgical resection is approximately 50% after 3–27 months [12,13]. Cytoreductive surgery with standard peritonectomy




Figure 3. The pelvis of the patient after pelvic peritonectomy.




Figure 4. Low grade peritoneal mesothelioma.

procedures in combination with HIPEC seems to be a rationale approach for the definitive treatment of this disease. Cytoreductive surgery makes possible complete resection of the tumor. The eradication of microscopic residual tumor is possible by heated intraperitoneal chemotherapy thus minimizing the risk of recurrence [14]. Modified cytoreductive surgery combined with HIPEC has been safely and effectively used in patients with recurrent multicystic peritoneal mesothelioma [7].

CONCLUSIONS

Complete cytoreductive surgery in combination with hyperthermic intraoperative intraperitoneal chemotherapy appears to be a rational therapeutic approach in multicystic peritoneal mesothelioma.

REFERENCES:

1. Safioleas MC, Constantinou K, Michael S et al: Benign multicystic peritoneal mesothelioma: a case report and review of the literature. *World J Gastroenterol*, 2006; 12: 5739–42
2. Søreide JA, Søreide K, Körner H et al: Benign peritoneal cystic mesothelioma. *World J Surg*, 2006; 30: 560–66
3. Sethna K, Mohamed F, Marchettini P et al: Peritoneal cystic mesothelioma: a case series. *Tumori*, 2003; 89: 31–35
4. Yan TD, Brun EA, Cerruto CA et al: Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. *Ann Surg Oncol*, 2007; 14: 41–49
5. Brigand C, Monneuse O, Mohamed F et al: Malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal chemohyperthermia: results of a prospective study. *Ann Surg Oncol*, 2006; 13: 405–12
6. Yan TD, Deraco M, Baratti D et al: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. *J Clin Oncol*, 2009; 27: 6237–42
7. Baratti D, Kusamura S, Sironi A et al: Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). *In Vivo*, 2008; 22: 153–58
8. Weiss SW, Tavassoli FA: Multicystic mesothelioma. An analysis of pathologic findings and biologic behavior in 37 cases. *Am J Surg Pathol*, 1988; 12: 737–46
9. Van Ruth S, Bronkhorst MWGA, von Coevorden F, Zoetmulder FAN: Peritoneal cystic mesothelioma: a case report and review of the literature. *EJSO*, 2002; 28: 192–95
10. De Stephano DB, Wesley JR, Heidelberg KP et al: Primitive cystic hepatic neoplasm of infancy with mesothelial differentiation: report of a case. *Pediatr Pathol*, 1985; 4: 291–302
11. Gonzalez-Moreno S, Yan H, Alcorn KW, Sugarbaker PH: Malignant transformation of benign cystic mesothelioma of the peritoneum. *J Surg Oncol*, 2002; 79: 249–51
12. De Toma G, Nicolanti V, Plocco M et al: Cystic peritoneal mesothelioma: report of a case. *Surg Today*, 2000; 30: 98–100
13. Romero JA, Kim EE, Kudelka AP et al: MRI of recurrent cystic mesothelioma: differential diagnosis of cystic pelvic masses. *Gynecol Obstet*, 1994; 54: 377–80
14. Sugarbaker PH: New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? *The Lancet Oncol*, 2006; 7: 69–76